20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3069% below fair value
$0.19+0.00 (+1.30%)
Close on Nov 17, 2026Market cap $2.39MP/E –Yield –
20/20 Biolabs gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 29.6%, against 20.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29.6% | +9.0 |
| FY2024 | Dec 31, 2024 | 20.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 41.7% | – |
| Q1 FY2026 | Mar 31, 2026 | 17.8% | – |
| Q2 FY2025 | Jun 30, 2025 | 30.5% | – |
| Q1 FY2025 | Mar 31, 2025 | 29.9% | – |
See a number that looks wrong?